[Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review].

Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol (2010) 0.91

Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma according to Helicobacter pylori infection status: a single-center experience. Gut Liver (2013) 0.86

Helicobacter pylori infection: new pathogenetic and clinical aspects. World J Gastroenterol (2014) 0.80

Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models. Dis Model Mech (2017) 0.78

Concurrent colonic mucosa-associated lymphoid tissue lymphoma and adenoma diagnosed after a positive fecal occult blood test: a case report. J Med Case Rep (2016) 0.77

A case of Helicobactor pylori negative low-grade gastric MALT lymphoma in an elderly female, successfully treated with rituximab. Am J Case Rep (2013) 0.75

Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol (2017) 0.75

Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther (2011) 3.16

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut (2010) 2.98

Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther (2010) 2.51

Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther (2015) 2.00

Systematic review: hepatitis-associated aplastic anaemia--a syndrome associated with abnormal immunological function. Aliment Pharmacol Ther (2009) 1.83

Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther (2014) 1.78

Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther (2006) 1.74

Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol (2005) 1.67

Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther (2011) 1.63

13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Dig Liver Dis (2000) 1.51

Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther (2011) 1.50

Prevalence of Helicobacter pylori infection in medical professionals in Spain. Eur J Gastroenterol Hepatol (1999) 1.42

Epidemiology of inflammatory bowel disease in Spain. A systematic review. Rev Esp Enferm Dig (2001) 1.39

Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis (2007) 1.39

Commentary: comparators in H. pylori eradication--stating the ethics of statins. Aliment Pharmacol Ther (2012) 1.38

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther (2000) 1.36

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther (2005) 1.34

The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther (2011) 1.15

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther (2010) 1.14

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2003) 1.14

Epinephrine injection versus epinephrine injection and a second endoscopic method in high risk bleeding ulcers. Cochrane Database Syst Rev (2007) 1.14

Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob Agents Chemother (1999) 1.11

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther (2003) 1.08

Letter: distinguishing PPI-responsive oesophageal eosinophilia from eosinophilic oesophagitis - still a long way to go. Aliment Pharmacol Ther (2014) 1.08

Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease. Aliment Pharmacol Ther (2014) 1.08

Letter: the irony of oral iron - not an underdog for post-gastrointestinal bleeding anaemia. Aliment Pharmacol Ther (2014) 1.08

Letter: acute severe ulcerative colitis - should all patients be treated equally? Aliment Pharmacol Ther (2014) 1.08

Meta-analysis: predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer. Aliment Pharmacol Ther (2011) 1.07

Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther (2011) 1.07

Letter: Persisting clinical symptoms in microscopic colitis in remission. Aliment Pharmacol Ther (2014) 1.07

Usefulness of manometry to select patients with anal fissure for controlled anal dilatation. Rev Esp Enferm Dig (2010) 1.07

Letter: infliximab in severe ulcerative colitis - is it useful for all patients? Aliment Pharmacol Ther (2013) 1.07

Letter: mucosal healing in ulcerative colitis--higher relevance than in Crohn's disease? Aliment Pharmacol Ther (2013) 1.07

Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided. Aliment Pharmacol Ther (2013) 1.06

Letter: PPI-responsive oesophageal eosinophilia--from initial scepticism to consistent prospective data. Aliment Pharmacol Ther (2014) 1.06

Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy--optimisation is the way forward. Aliment Pharmacol Ther (2013) 1.06

Letter: should colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis? Aliment Pharmacol Ther (2013) 1.06

Letter: Bismuth quadruple therapy with Pylera for H. pylori infection. Aliment Pharmacol Ther (2014) 1.05

Letter: psychological remission - a future endpoint in inflammatory bowel disease? Aliment Pharmacol Ther (2014) 1.05

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (2012) 1.05

Letter: predictors of severe disease in ulcerative colitis - the same or different in Crohn's disease? Aliment Pharmacol Ther (2014) 1.04

Collagenous colitis in Spain: a report of nine new cases. Rev Esp Enferm Dig (1999) 1.00

Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther (2008) 0.99

Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther (2012) 0.99

The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther (2013) 0.97

Letter: Recommendations for the management of latent tuberculosis infection in IBD patients may not be applicable in all settings. Aliment Pharmacol Ther (2013) 0.96

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther (2002) 0.96

Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther (2008) 0.95

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther (2001) 0.94

Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori. Scand J Gastroenterol (1997) 0.91

Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther (2013) 0.89

Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther (2003) 0.89

Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther (2007) 0.89

Angiogenesis in inflammatory bowel disease. Eur J Clin Invest (2008) 0.89

Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol (2012) 0.89

[Endoscopic choledochoduodenostomy in the treatment of impacted calculi in Vater's papilla]. Rev Esp Enferm Dig (1991) 0.87

[Anemia and inflammatory bowel disease]. Rev Esp Enferm Dig (2008) 0.85

The colorectal carcinoma prognosis factors. Significance of diagnosis delay. Rev Esp Enferm Dig (2006) 0.85

Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment Pharmacol Ther (2013) 0.85

Concordance between noninvasive tests in detecting Helicobacter pylori and potential use of serology for monitoring eradication in gastric ulcer. J Clin Gastroenterol (2000) 0.84

Factors involved in the pathogenesis of Helicobacter pylori infection. Rev Esp Enferm Dig (2006) 0.83

Impact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression: a multinational primary care study. Aliment Pharmacol Ther (2013) 0.83

Prevalence of macrocreatinkinase type 1 in patients with inflammatory bowel disease. Dig Dis Sci (2007) 0.82

Intensification of infliximab therapy in Crohn's disease: efficacy and safety. J Crohns Colitis (2011) 0.82

Usefulness of the combined IgG and IgA antibody determinations for serodiagnosis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol (1997) 0.82

[Helicobacter pylori infection: antibiotic resistance]. Rev Esp Enferm Dig (2007) 0.81

High seroprevalence of Helicobacter pylori infection in coronary heart disease. Lancet (1995) 0.81

High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther (2012) 0.81

Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis (2011) 0.81

Spanish scientific output on Helicobacter pylori. A study through Medline. Rev Esp Enferm Dig (2006) 0.80

Helicobacter pylori infection and precancerous lesions of the stomach. Hepatogastroenterology (2002) 0.80

[Is there any association between Helicobacter pylori infection and peptic esophagitis?]. Med Clin (Barc) (1995) 0.80

Predictors of response to infliximab in patients with fistulizing Crohn's disease. Rev Esp Enferm Dig (2004) 0.79

Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther (2012) 0.79

Health care costs of complex perianal fistula in Crohn's disease. Dig Dis Sci (2013) 0.79

Letter: measurement of anti-TNF-α levels and antibodies against the drug. Aliment Pharmacol Ther (2013) 0.78

[Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease]. Gastroenterol Hepatol (2010) 0.78

Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig (2005) 0.78

Helicobacter pylori: its discovery and relevance for medicine. Rev Esp Enferm Dig (2006) 0.78

Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther (2007) 0.78

[The importance of obtaining biopsies of the gastric body in the follow-up after eradicating treatment of Helicobacter pylori]. Med Clin (Barc) (1995) 0.78

Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. Eur J Med Chem (2013) 0.78

Geographic differences and the role of cagA gene in gastroduodenal diseases associated with Helicobacter pylori infection. Rev Esp Enferm Dig (2001) 0.77

[The attitude in a failure to eradicate Helicobacter pylori: surrender or fight?]. Med Clin (Barc) (1998) 0.77

ABO blood groups, rhesus factor and Helicobacter pylori. Rev Esp Enferm Dig (1998) 0.77

Helicobacter pylori infection and gastric mucosal epithelial cell apoptosis. Rev Esp Enferm Dig (2005) 0.77

[Basal concentrations of gastrin and pepsinogen I and II in gastric ulcer: influence of Helicobacter pylori infection and usefulness in the control of the eradication]. Gastroenterol Hepatol (2001) 0.77

[Eosinophilic esophagitis in the adult--clinical, endoscopic, pH-metric, and manometric findings]. Rev Esp Enferm Dig (2008) 0.76

Rescue therapy with levofloxacin after multiple H. pylori treatment failures. Aliment Pharmacol Ther (2005) 0.76

Predictive graphical model, network-based medical tool for the prognosis of chronic hepatitis C patients treated with peg-interferon plus ribavirin. Aliment Pharmacol Ther (2008) 0.76

Gastric angiogenesis and Helicobacter pylori infection. Rev Esp Enferm Dig (2006) 0.76

[Antibodies against Helicobacter pylori in saliva. Study of their validity versus breath test and its agreement with serology]. Aten Primaria (2000) 0.76

[Efficacy of four widely used techniques of the diagnosis of Helicobacter pylori infection in gastric ulcer disease]. Rev Clin Esp (2000) 0.75

Is the string test a useful alternative to gastroscopy with biopsy for H. pylori identification? Rev Esp Enferm Dig (2006) 0.75

Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding. Aliment Pharmacol Ther (2008) 0.75

Azathioprine plus ribavirin treatment and pancytopenia. Aliment Pharmacol Ther (2009) 0.75

Letter: TPMT - not all that glitters is gold. Aliment Pharmacol Ther (2012) 0.75

Lamivudine response of IgM anti-HBc chronic hepatitis B patients. Aliment Pharmacol Ther (2006) 0.75

Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther (2010) 0.75